Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropeginterferon Alfa-2b Add-on to Ruxolitinib in Myelofibrosis
NCT07521046Phase 1Recruiting
- Sponsor
- University of Utah
- Start
- Aug 2026
- Primary completion
- Aug 2029
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ropeginterferon alfa-2b in myelofibrosis (MF), sponsored by University of Utah. Primary endpoint: Frequency of Adverse Events and Serious Adverse Events at 2 years. Started Aug 2026; status: recruiting.
02
Drugs
ropeginterferon alfa-2b
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT07521046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07521046.